ProCE Banner Activity

CME

Immunotherapy Approaches for Urothelial Bladder Cancer: Expert Guidance Through Challenging Cases Exploring the Fundamental Changes in Patient Care

Multimedia
In this virtual presentation, Elizabeth R. Plimack, MD, MS discusses the clinical rationale and data on the use of immune checkpoint inhibitors for patients with advanced bladder cancer. Afterwards, download the slides and use the treatment decision tool for your practice.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: April 30, 2018

Expiration: April 29, 2019

No longer available for credit.

Share

Faculty

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck Oncology

Target Audience

This program is intended for physicians, nurses, and other healthcare professionals who provide care for patients with bladder cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Differentiate the mechanisms of action and clinical properties of immunotherapy approaches for the treatment of patients with bladder cancer
  • Evaluate the available efficacy and safety data on different immunotherapies and their clinical implications on current therapy decisions in bladder cancer
  • Plan treatment strategies for patients with bladder cancer that include immune checkpoint inhibitors

Faculty Disclosure

Primary Author

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Clovis, Eli Lilly and Company, Exelixis, Genentech, Horizon Pharma, Inovio, Novartis, and Pfizer and funds for research support from Astellas, AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Peloton, and Pfizer.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no significant financial relationships to disclose.

Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD has no significant financial relationships to disclose.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no significant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD has no significant financial relationships to disclose.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD has no significant financial relationships to disclose.

Instructions for Credit


Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The Postgraduate Institute for Medicine designates this online activity for a maximum of 1.0 AMA PRA Category 1 Creditâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 30, 2018, through April 29, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ clinical competence in applying recent practice-changing findings regarding immunotherapies for the treatment of bladder cancer.